[Skip to Content]
[Skip to Content Landing]
August 16, 1985

Herpes Zoster: Adenosine Monophosphate for the Prevention of Post-Neuralgia

Author Affiliations

Englewood Hospital Englewood, NJ
Ohio University Athens
Columbia University School of Public Health New York

JAMA. 1985;254(7):912. doi:10.1001/jama.1985.03360070050021

To the Editor.—  In the March 8 issue of The Journal, our article, "Herpes Zoster: The Treatment and Prevention of Neuralgia With Adenosine Monophosphate,"1 published together with an editorial by Sherlock and Corey,2 in which they suggest "a large dose of caution." We agree that there is a need for additional investigations, especially for testing in an expanded patient population, pharmacokinetic evaluations, and in vitro and animal studies pertaining to the efficacy and mechanism of action of adenosine monophosphate (AMP) against the herpesviruses. In fact, we suggested the need for future studies in our article. We strongly believe, however, that there is no evidence to promote "concerns about the potential toxic effects of AMP in humans."Sherlock and Corey based much of their concern on reports of in vitro cellular (not human) toxicity of adenosine (not AMP). Adenosine monophosphate is a naturally occurring metabolite, not an analogue drug